Victor Wroblewski

Victor Wroblewski

UNVERIFIED PROFILE

Are you Victor Wroblewski?   Register this Author

Register author
Victor Wroblewski

Victor Wroblewski

Publications by authors named "Victor Wroblewski"

Are you Victor Wroblewski?   Register this Author

40Publications

819Reads

48Profile Views

Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I] galcanezumab in male rats.

Cephalalgia 2019 Sep 19;39(10):1241-1248. Epub 2019 Apr 19.

1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419844711
Publisher Site
http://dx.doi.org/10.1177/0333102419844711DOI Listing
September 2019

The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.

MAbs 2015 4;7(6):1084-93. Epub 2015 Sep 4.

a Departments of Drug Disposition and Development/Commercialization, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center , Indianapolis , IN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1075109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966429PMC
August 2016

Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.

MAbs 2016 07;8(5):969-82

a Department of Drug Disposition, Development/ Commercialization , Lilly Research Laboratories, Lilly Corporate Center , Indianapolis , Indiana , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2016.1178435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968112PMC
July 2016

A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets.

J Biol Chem 2016 May 28;291(21):11337-47. Epub 2016 Mar 28.

From the Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M116.714287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900278PMC
May 2016

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

MAbs 2015 ;7(3):483-93

a Department of Drug Disposition Development/Commercialization; Lilly Research Laboratories; Eli Lilly and Company Corporate Center , Indianapolis , IN USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1016696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622971PMC
March 2016

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

J Lipid Res 2015 Nov 20;56(11):2124-32. Epub 2015 Sep 20.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1194/jlr.M061903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617399PMC
November 2015

Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose.

Drug Metab Dispos 2015 Oct 14;43(10):1477-83. Epub 2015 Jul 14.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.115.064337DOI Listing
October 2015

Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.

J Pharmacol Exp Ther 2015 Sep 26;354(3):350-7. Epub 2015 Jun 26.

Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium (S.V., A.V.H., J.d.H.); Eli Lilly and Company, Indianapolis, Indiana (R.J.B., D.M., V.J.W., E.C.C.); and Atlas Venture, Cambridge, Massachusetts (D.G.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.115.224212DOI Listing
September 2015

Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

MAbs 2012 Mar-Apr;4(2):267-73. Epub 2012 Mar 1.

Eli Lilly Research Laboratories; Eli Lilly Corporate Center; Indianapolis, IN USA; Departments of Drug Disposition Development/Commercialization; Eli Lilly Research Laboratories; Eli Lilly Corporate Center; Indianapolis, IN USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/mabs.4.2.19364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361662PMC
February 2015

Application of FcRn binding assays to guide mAb development.

Drug Metab Dispos 2014 Nov 14;42(11):1867-72. Epub 2014 Jul 14.

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.114.059089DOI Listing
November 2014

Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments.

MAbs 2013 Mar-Apr;5(2):288-96. Epub 2013 Feb 8.

Drug Disposition, Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/mabs.23508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893239PMC
December 2013

FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.

Drug Metab Dispos 2012 Aug 14;40(8):1545-55. Epub 2012 May 14.

Departments of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, S. Delaware St., Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.112.045864
Publisher Site
http://dx.doi.org/10.1124/dmd.112.045864DOI Listing
August 2012

A dual-monoclonal sandwich ELISA specific for hepcidin-25.

Clin Chem 2010 Nov 16;56(11):1725-32. Epub 2010 Sep 16.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.clinchem.org/cgi/doi/10.1373/clinchem.2010.151522
Publisher Site
http://dx.doi.org/10.1373/clinchem.2010.151522DOI Listing
November 2010

Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency.

Br J Haematol 2009 Mar 20;144(5):789-93. Epub 2008 Dec 20.

Department of Medicine II, Medical University of Innsbruck, Innsbruck, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2008.07535.xDOI Listing
March 2009

Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.

Mol Biol Cell 2008 Dec 8;19(12):5490-505. Epub 2008 Oct 8.

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.molbiolcell.org/doi/10.1091/mbc.e07-02-0101
Publisher Site
http://dx.doi.org/10.1091/mbc.e07-02-0101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592658PMC
December 2008

Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors.

Transfusion 2008 Oct 24;48(10):2197-204. Epub 2008 Jul 24.

Blood Research Institute, Blood Center of Wisconsin, Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin 53226-3548, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1537-2995.2008.01823.xDOI Listing
October 2008

Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry.

Blood 2007 Aug 13;110(3):1048-54. Epub 2007 Apr 13.

Department of Drug Disposition Bioproducts, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-11-05
Publisher Site
http://dx.doi.org/10.1182/blood-2006-11-057471DOI Listing
August 2007

Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections.

Toxicol Pathol 2007 Jun;35(4):541-8

Eli Lilly & Company, Drug Disposition Development/Commercialization. Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01926230701338958DOI Listing
June 2007

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Endocrinology 2007 Feb 26;148(2):774-81. Epub 2006 Oct 26.

Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2006-1168DOI Listing
February 2007

Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates.

Drug Metab Dispos 2007 Jan 18;35(1):86-94. Epub 2006 Oct 18.

Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.106.011734DOI Listing
January 2007

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.

J Biol Chem 2007 Jan 29;282(3):1709-17. Epub 2006 Nov 29.

Department of Drug Disposition Development/Commercialization and Biotechnology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M607161200DOI Listing
January 2007

In vivo deamidation characterization of monoclonal antibody by LC/MS/MS.

Anal Chem 2005 Mar;77(5):1432-9

Biopharmaceutical Product Development, Biotechnology Discovery Research, Drug Disposition Development/Commercialization, and Manufacturing Science and Technology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ac0494174DOI Listing
March 2005

Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.

Drug Metab Dispos 2003 Apr;31(4):502-7

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.31.4.502DOI Listing
April 2003

Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.

Biochem Pharmacol 2003 Feb;65(4):657-67

Department of Drug Disposition Development/Commercialization, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(02)01612-xDOI Listing
February 2003